Original Biomedicals Co Ltd(TW:6483)
NT$15.050.30 (-1.31%)
TW:6483
Original Biomedicals Co Ltd financials statements
NT$15.05
At close:0.30 (-1.31%)
Original Biomedicals Co Ltd (6483) Ratios
Original Biomedicals Co Ltd Ratios
TW:6483's free cash flow for Q2 2026 was NT$-72.48M. For the 2026 fiscal year, TW:6483's free cash flow was decreased by NT$-2.30M and operating cash flow was NT$-70.18M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.74 | 17.77 | 12.26 | 5.77 | 11.09 |
| Quick Ratio | 9.74 | 17.77 | 12.26 | 5.77 | 11.09 |
| Cash Ratio | 7.95 | 10.50 | 8.21 | 1.35 | 0.99 |
| Solvency Ratio | -3.55 | -2.76 | -1.21 | -1.12 | -0.89 |
| Operating Cash Flow Ratio | -5.70 | -5.83 | -1.06 | -2.93 | -2.93 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 137.93M | NT$ 232.19M | NT$ 299.33M | NT$ 30.93M | NT$ 66.19M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.04 | 0.04 | 0.20 | 0.15 |
| Debt-to-Equity Ratio | 0.07 | 0.05 | 0.05 | 0.29 | 0.19 |
| Debt-to-Capital Ratio | 0.07 | 0.04 | 0.05 | 0.22 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.17 | 1.09 | 1.13 | 1.42 | 1.26 |
| Debt Service Coverage Ratio | -156.08 | -75.72 | -45.38 | -26.08 | -17.22 |
| Interest Coverage Ratio | -177.28 | -90.24 | -53.97 | -33.59 | -23.55 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.18 | 0.19 | 0.35 | 0.45 | 0.53 |
| Net Debt to EBITDA | 1.33 | 2.12 | 4.26 | -0.19 | -0.51 |
| Profitability Margins | |||||
| Gross Profit Margin | 80.31% | 0.00% | 81.40% | 88.79% | 0.00% |
| EBIT Margin | -26488.19% | 0.00% | -136193.02% | -36524.30% | 0.00% |
| EBITDA Margin | -24169.82% | 0.00% | -115874.42% | -29156.07% | 0.00% |
| Operating Profit Margin | -27453.02% | 0.00% | -137818.60% | -37547.66% | 0.00% |
| Pretax Profit Margin | -26643.04% | 0.00% | -138746.51% | -37642.06% | 0.00% |
| Net Profit Margin | -26643.04% | 0.00% | -138746.51% | -37642.06% | 0.00% |
| Continuous Operations Profit Margin | -26643.04% | 0.00% | -138746.51% | -37642.06% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.05% | 95.74% | 100.67% | 100.25% | 103.72% |
| Return on Assets (ROA) | -55.19% | -26.85% | -16.10% | -41.08% | -24.66% |
| Return on Equity (ROE) | -64.31% | -29.38% | -18.16% | -58.23% | -31.05% |
| Return on Capital Employed (ROCE) | -62.60% | -29.57% | -17.29% | -45.82% | -25.35% |
| Return on Invested Capital (ROIC) | -61.08% | -29.07% | -17.08% | -44.01% | -24.75% |
| Return on Tangible Assets | -55.19% | -26.85% | -16.10% | -41.08% | -24.66% |
| Earnings Yield | -11.09% | -9.93% | -7.03% | -5.00% | -4.73% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.03 | 0.00 | 0.33 | 2.89 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 13398.66 | 0.00 | 1103.49 | 126.21 | 0.00 |
| Days of Sales Outstanding | 13398.66 | 0.00 | 1103.49 | 126.21 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 13398.66 | 0.00 | 1103.49 | 126.21 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.45 | -1.28 | -0.60 | -0.65 | -0.60 |
| Free Cash Flow Per Share | -1.47 | -1.30 | -0.60 | -0.66 | -0.65 |
| Dividend Paid and CapEx Coverage Ratio | -101.17 | -45.71 | -94.85 | -65.13 | -12.96 |
| Capital Expenditure Coverage Ratio | -101.17 | -45.71 | -94.85 | -65.13 | -12.96 |
| Operating Cash Flow Coverage Ratio | -8.58 | -7.02 | -1.82 | -1.53 | -1.21 |
| Operating Cash Flow to Sales Ratio | -251.99 | 0.00 | -686.02 | -284.28 | 0.00 |
| Free Cash Flow Yield | -10.59% | -11.38% | -3.52% | -3.83% | -3.75% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.99 | -10.04 | -14.21 | -20.00 | -21.23 |
| Price-to-Sales (P/S) Ratio | 2403.15 | 0.00 | 19722.64 | 7528.41 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.80 | 2.96 | 2.58 | 11.65 | 6.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.44 | -8.79 | -28.45 | -26.08 | -26.66 |
| Price-to-Operating Cash Flow Ratio | -9.54 | -8.98 | -28.75 | -26.48 | -28.71 |
| Price-to-Earnings Growth (PEG) Ratio | -0.26 | 1.74 | -0.35 | -3.24 | 0.59 |
| Enterprise Value Multiple | -8.61 | -9.37 | -12.76 | -26.01 | -30.49 |
| Enterprise Value | 792.94M | 615.79M | 635.64M | 811.45M | 728.06M |
| EV to EBITDA | -8.61 | -9.37 | -12.76 | -26.01 | -30.49 |
| EV to Sales | 2081.22 | 0.00 | 14782.27 | 7583.68 | 0.00 |
| EV to Free Cash Flow | -8.18 | -7.16 | -21.32 | -26.27 | -27.11 |
| EV to Operating Cash Flow | -8.26 | -7.32 | -21.55 | -26.68 | -29.20 |
| Tangible Book Value Per Share | 2.39 | 3.87 | 6.66 | 1.48 | 2.62 |
| Shareholders’ Equity Per Share | 2.39 | 3.87 | 6.66 | 1.48 | 2.62 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.54 | -1.14 | -1.21 | -0.86 | -0.81 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.01 | 1.02 | 1.03 | 1.04 |
| Research & Development to Revenue | 124.03 | 0.00 | 574.67 | 214.12 | 0.00 |
| SG&A to Revenue | 151.30 | 0.00 | 804.33 | 162.24 | 0.00 |
| Stock-Based Compensation to Revenue | 0.40 | 0.00 | 156.21 | 3.21 | 0.00 |
| Income Quality | 0.95 | 1.12 | 0.49 | 0.76 | 0.74 |
Currency in TWD
